Reviewed by Michael Gill, B. Sc.
Image of Re+Active Therapy and Wellness Centre/ UCLA in Los Angeles, United States.
Phase-Based Progress Estimates

Physcial Activity Interventionfor Huntington Disease

All Sexes
Huntington's disease (HD) is a genetic, degenerative neurological disease that affects individuals in their third-fourth decade of life and individuals can live 15-20 years with manifest HD. The complex disease symptoms, including motor, cognitive and behavioural impairments, result in loss of functional independence and progressive escalation of healthcare costs. The personal, social and economic consequences of HD are devastating, especially as there are currently no disease modification therapies available. Environmental factors, including exercise and physical activity, have the potential to minimize the functional impact of HD. Animal models of HD have provided the first evidence that exercise has the potential to delay or alter disease progression. A range of studies in clinical populations have shown that short-term exercise (< 3 months) is well tolerated and has the potential to improve quality of life, fitness and motor impairments in HD. Despite these promising studies, there are critical knowledge gaps that prevent the intelligent application of exercise as a therapeutic intervention in HD. Firstly, there have been no prospective evaluations of the potential role of physical activity and exercise in disease modification in HD. To date, only retrospective data has suggested that lifestyle factors, including sedentary behavior, could negatively affect disease progression in HD. Secondly, it is not known if sustained exercise (> 3 months) is feasible, and if it has the potential to improve cognitive outcomes, such as has been shown in other neurodegenerative diseases. Such longer-term studies are essential to elucidate the potential for exercise to have a disease-modifying effect; the mechanisms through which such improvement may occur have yet to be explored. In this trial, the investigators will employ a systematic approach for routinely collecting prospective physical activity and fitness data and monitoring physical activity behaviour in 120 individuals with HD. The investigators will use a database to track physical activity and exercise behaviour alongside standardized disease-specific outcome measures during two annual visits. Assessment will incorporate VO2max, a surrogate measure of fitness and a direct measure of oxygen uptake related to central nervous system (CNS) function and structure, and the use of wearable technologies (Gene-activ activity monitors) that capture and quantify dose (frequency, duration, intensity) of physical activity in a large HD cohort. The investigators will further conduct a within-cohort randomized control trial (RCT) of a 12-month exercise intervention in HD, comparing a supported structured aerobic exercise training program to activity as usual. This intervention will also incorporate a physical activity coaching program developed and evaluated by our group with a view to encouraging longer term exercise uptake.
Waitlist Available
Has No Placebo
Re+Active Therapy and Wellness Centre/ UCLA (+1 Sites)Lori Quin, PhD
22 Huntingtons Disease Clinical Trials Near Me
Top Hospitals for Huntingtons Disease Clinical Trials
Image of The University of Texas Health Science Center at Houston in Texas.
The University of Texas Health Science Center at Houston
3Active Trials
3All Time Trials for Huntingtons Disease
2019First Huntingtons Disease Trial
Image of Sage Investigational Site in District of Columbia.
Sage Investigational Site
2Active Trials
2All Time Trials for Huntingtons Disease
2022First Huntingtons Disease Trial
Top Cities for Huntingtons Disease Clinical Trials
Image of Houston in Texas.
7Active Trials
The University of Texas Health Science Center at HoustonTop Active Site
Image of Washington in District of Columbia.
5Active Trials
Sage Investigational SiteTop Active Site
Huntington's Disease Clinical Trials by Phase of Trial
Most Recent Huntingtons Disease Clinical Trials
Clinical Trial
Began Recruiting Date
Top Treatments for Huntingtons Disease Clinical Trials
Treatment Name
Active Huntingtons Disease Clinical Trials
All Time Trials for Huntingtons Disease
First Recorded Huntingtons Disease Trial
active tDCS
Movement to Music
Recently Completed Studies with FDA Approved Treatments for Huntingtons Disease
Annexon, Inc.
Hoffmann-La Roche

What Are Huntington's Disease Clinical Trials?

Huntington's disease is an inherited, rare disorder that results in a gradual degeneration of the brain's nerve cells. This disease has a major impact on the functional abilities of an individual and causes psychiatric, cognitive, and movement disorders.

The symptoms of this disease can occur at any time but typically start appearing between the ages of 30 and 40. If this disorder appears in an individual below 20 years, it is known as juvenile Huntington's disease. In this case, the progression of the disease is faster, and the symptoms slightly differ.

While multiple treatments and medications help manage the symptoms, there is no cure, and no treatment can prevent behavioral, mental, and physical decline.

Why Is Huntington's Disease Being Studied Through Clinical Trials?

One in 10,000 individuals in the US suffers from Huntington's disease. Around 16% of all Huntington's cases are juvenile Huntington's disease. This disease isn't prevalent in a particular population since all ethnic groups and races are affected.

There is ongoing research and clinical trials to find innovative treatments to cure this disease. Some progress has been made in finding potential means of halting or slowing down the progression of this disease. Moreover, multiple treatments are being tested in clinical trials to determine their effectiveness and safety.

What Are The Types of Treatments Available For Huntington's Disease?

While there is currently no treatment to slow or cure Huntington's disease progression, there are multiple medications that help in managing the symptoms. Medications, including amantadine, tetrabenazine, and haloperidol, are given to manage the unusual movements.

The healthcare provider prescribes tetrabenazine and haloperidol to control delusional thoughts and hallucinations. Suicidal thoughts and depression are also common in Huntington's disease, for which antianxiety and antidepressants are prescribed.

What Are Some Recent Breakthrough Clinical Trials For Huntington's Disease?

2022: The Pridopidine phase 3 study has been identified as a breakthrough in Huntington's disease field and could assist in finding the treatment. The PROOF-HD clinical trial is an ongoing study that indicates pridopidine as a potential treatment for ALS, Huntington’s, and other neurodegenerative diseases. Pridopidine activates and binds the Sigma-1 receptor located in the brain at high levels. The drug can enhance neurotrophic factor production when this receptor is activated. These protein levels are at low levels in individuals suffering from Huntington's, and by targeting them, researchers believe there could be therapy or treatment to slow down the disease's progression.

2021: The scientists at the University of Cambridge and ULC have identified a mechanism that could prevent the progression of this disease in the cells. Researchers believe this breakthrough could result in innovative therapies for Huntington's disease. Medication that could potentiate or mimic the mismatch repair of FAN inhibition might alter the course of this disease. The team has started using this discovery to find effective therapies for Huntington's disease.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Huntington's Disease Clinical Trials Research?

European Huntington’s Disease Network: This is a nonprofit network dedicated to accelerating the research related to Huntington's disease. The network supports and funds clinical and research development at different stages – from applied and basic science to the development and clinical trials of clinical assessment tools, treatment strategies, and other guidelines.

Huntington’s Disease Society of America (HDSA): This is a nonprofit institution supporting the individuals affected by this disease. The team is dedicated to providing education, funding research and trials, and providing authentic information to help individuals with Huntington's disease.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 20th, 2021

Last Reviewed: November 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Rodrigues FB, Wild EJ. Huntington's Disease Clinical Trials Corner: April 2020. J Huntingtons Dis. 2020;9(2):185-197. doi: 10.3233/JHD-200002. Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Falconer RA, Ahn J, Li Z, Moussa C. Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. J Parkinsons Dis. 2016 Jul 11;6(3):503-17. doi: 10.3233/JPD-160867. Rodrigues FB, Quinn L, Wild EJ. Huntington's Disease Clinical Trials Corner: January 2019. J Huntingtons Dis. 2019;8(1):115-125. doi: 10.3233/JHD-190001. Review. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. Epub 2002 Jul 29. Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60. Drew CJG, Quinn L, Hamana K, Williams-Thomas R, Marsh L, Dimitropoulou P, Playle R, Griffin BA, Kelson M, Schubert R, Muratori L, Reilmann R, Rosser A, Busse M. Physical Activity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease. Phys Ther. 2019 Sep 1;99(9):1201-1210. doi: 10.1093/ptj/pzz075. Quinn L, Playle R, Drew CJG, Taiyari K, Williams-Thomas R, Muratori LM, Hamana K, Griffin BA, Kelson M, Schubert R, Friel C, Morgan-Jones P, Rosser A, Busse M; PACE-HD site investigators. Physical activity and exercise outcomes in Huntington's disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington's disease. Parkinsonism Relat Disord. 2022 Aug;101:75-89. doi: 10.1016/j.parkreldis.2022.06.013. Epub 2022 Jun 29. Quinn L, Playle R, Drew CJG, Taiyari K, Williams-Thomas R, Muratori LM, Hamana K, Griffin BA, Kelson M, Schubert R, Friel C, Morgan-Jones P, Rosser A, Busse M; PACE-HD site investigators. Physical activity and exercise outcomes in Huntington's disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington's disease. Parkinsonism Relat Disord. 2022 Jun 29;101:75-89. doi: 10.1016/j.parkreldis.2022.06.013. [Epub ahead of print] Robbins CB, Akrobetu D, Ma JP, Stinnett SS, Soundararajan S, Liu AJ, Johnson KG, Grewal DS, Fekrat S. ASSESSMENT OF RETINAL MICROVASCULAR ALTERATIONS IN INDIVIDUALS WITH AMNESTIC AND NONAMNESTIC MILD COGNITIVE IMPAIRMENT USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2022 Jul 1;42(7):1338-1346. doi: 10.1097/IAE.0000000000003458.